Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accumulated Expenses (2016 - 2024)

Historic Accumulated Expenses for United Therapeutics (UTHR) over the last 16 years, with Q4 2024 value amounting to $338.5 million.

  • United Therapeutics' Accumulated Expenses rose 1576.61% to $338.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $338.5 million, marking a year-over-year increase of 1576.61%. This contributed to the annual value of $338.5 million for FY2024, which is 1576.61% up from last year.
  • United Therapeutics' Accumulated Expenses amounted to $338.5 million in Q4 2024, which was up 1576.61% from $292.4 million recorded in Q4 2023.
  • United Therapeutics' Accumulated Expenses' 5-year high stood at $338.5 million during Q4 2024, with a 5-year trough of $170.8 million in Q4 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $225.8 million (2022), whereas its average is $242.1 million.
  • In the last 5 years, United Therapeutics' Accumulated Expenses tumbled by 661.56% in 2021 and then surged by 3220.14% in 2022.
  • United Therapeutics' Accumulated Expenses (Quarter) stood at $182.9 million in 2020, then dropped by 6.62% to $170.8 million in 2021, then surged by 32.2% to $225.8 million in 2022, then rose by 29.5% to $292.4 million in 2023, then grew by 15.77% to $338.5 million in 2024.
  • Its last three reported values are $338.5 million in Q4 2024, $292.4 million for Q4 2023, and $225.8 million during Q4 2022.